🔎 Trials Near Me

ホーム › 頭頸部扁平上皮癌

米国で参加者を募集している頭頸部扁平上皮癌の臨床試験

米国全土の拠点で、頭頸部扁平上皮癌に関する178件の研究が参加者を募集しています。

最も多くの研究がある都市

州別

最近更新された研究

公式研究テキスト（英語）

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06992427

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06788990

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06265285

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07189871

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07090499

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06589804

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07085091

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07814248

A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07744126

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07360314

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05877599

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

被験者募集中第1相
18歳〜74歳 · 全性別 · 2026/09/25更新 · NCT07219212

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05136196

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07276399

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

被験者募集中第3相
60歳以上 · 全性別 · 2026/09/25更新 · NCT04892173

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06980038

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06385080

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT07229313

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379

Intratumoral N17350 in Advanced Solid Tumors

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07339176

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

被験者募集中第2相
18歳〜79歳 · 全性別 · 2026/09/22更新 · NCT04671667

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT06736379

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。